NR4A3

Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2024

Retrieved on: 
Monday, May 6, 2024
Lyell, Triple-negative breast cancer, Colorectal cancer, Research, IND, TIL, Patient, NR4A3, Workforce, Memory, AACR, NSCLC, TNBC, GAAP, G&A, Lung cancer, Pharmaceutical industry

Initial data from at least 20 patients from the Phase 1 clinical trial of LYL797 are expected this quarter.

Key Points: 
  • Initial data from at least 20 patients from the Phase 1 clinical trial of LYL797 are expected this quarter.
  • Initial clinical and translational data from the Phase 1 trial of LYL845 are expected in the second half of 2024.
  • Research and development (R&D) expenses were $43.2 million for the first quarter ended March 31, 2024, compared to $44.6 million for the same period in 2023.
  • The decrease in first quarter 2024 non-GAAP R&D expenses was primarily driven by a decrease in personnel-related expenses.

Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2023

Retrieved on: 
Wednesday, February 28, 2024
NSCLC, Research, Gene, GSK, TIL, SITC, Growth, AP-1 transcription factor, Cell, International Society, NR4A3, Annual general meeting, Lung cancer, Society, Triple-negative breast cancer, GAAP, Biomarker, Phenotype, TNBC, Patient, Organization, Survival, TCR, Lyell, GSK plc, ISSCR, G&A, Literature, Workforce, IND, Corporation, Colorectal cancer, Vaccine

The study includes patients with relapsed or refractory triple-negative breast cancer (TNBC) or non-small cell lung cancer (NSCLC).

Key Points: 
  • The study includes patients with relapsed or refractory triple-negative breast cancer (TNBC) or non-small cell lung cancer (NSCLC).
  • The increase in fourth quarter 2023 non-GAAP R&D expenses was driven by an increase in research and laboratory costs primarily associated with clinical trials.
  • The decrease in both fourth quarter 2023 and annual 2023 G&A expenses were both primarily driven by decreases in non-cash stock-based compensation.
  • The decrease in 2023 non-GAAP G&A expenses was driven by a decrease in legal and corporate expenses.

Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2023

Retrieved on: 
Tuesday, November 7, 2023
Science, Research, NR4A3, CAR, NSCLC, IND, Literature, Colorectal cancer, ROR1, G&A, Workforce, GSK plc, GAAP, Phenotype, TIL, R, Lyell, TNBC, SITC, Immunotherapy, Clinical trial, Wine Cellar Innovations, Abstract, GSK, Triple-negative breast cancer, Lung cancer, Society, Patient, Pharmaceutical industry, Vaccine, Medical imaging

An approximately 25% reduction in workforce associated with this prioritization is expected to be completed in the fourth quarter of 2023.

Key Points: 
  • An approximately 25% reduction in workforce associated with this prioritization is expected to be completed in the fourth quarter of 2023.
  • Lyell is advancing four wholly-owned product candidates with two product candidates in Phase 1 clinical development, LYL797 and LYL845.
  • Non‑GAAP G&A expenses, which exclude non-cash stock-based compensation, for the third quarter ended September 30, 2023, were $9.5 million, compared to $11.4 million for the same period in 2022.
  • The decrease in third quarter 2023 non-GAAP G&A expenses was driven by a decrease in legal, consulting and other administrative expenses.

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2023

Retrieved on: 
Tuesday, August 8, 2023
GSK, GSK plc, TIL, ISSCR, Clinical trial, Lyell, G&A, GAAP, Research, Biomarker, Lung cancer, NR4A3, Organization, CAR, Patient, Colorectal cancer, SAN, Corporation, Annual general meeting, Growth, CAR T cell, R, International Society for Stem Cell Research, IND, International Society, ROR1, Pharmaceutical industry, Management, Vaccine, Medical imaging

Lyell reported a net loss of $63.9 million for the second quarter ended June 30, 2023, compared to a net loss of $36.3 million for the same period in 2022.

Key Points: 
  • Lyell reported a net loss of $63.9 million for the second quarter ended June 30, 2023, compared to a net loss of $36.3 million for the same period in 2022.
  • Revenue was approximately zero for the second quarter ended June 30, 2023, compared to $35.7 million for the same period in 2022.
  • The decrease in second quarter 2023 G&A expenses was primarily driven by changes in non-cash stock-based compensation.
  • The decrease in second quarter 2023 non-GAAP G&A expenses was driven by a decrease in legal, consulting and other administrative expenses.

Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2022

Retrieved on: 
Tuesday, February 28, 2023
TIL, Roivant Sciences, EPI, The Society, GSK, Survival, Research, Cell, Annual general meeting, GAAP, Gene, CAR, Immunotherapy, Patient, R, Neoplasm, ROR1, SITC, AP-1 transcription factor, Lyell, Cell proliferation, G&A, Society, Lung cancer, Cryptocurrency, Pharmaceutical industry, Vaccine, Medical imaging, IND, NR4A3

Initial clinical data from the Phase 1 trial of LYL797 are expected in the first half of 2024.

Key Points: 
  • Initial clinical data from the Phase 1 trial of LYL797 are expected in the first half of 2024.
  • LYL119 incorporates four of Lyell’s stackable reprogramming technologies, including two novel technologies – a genetic knockout of NR4A3 (NR4A3-KO) and Stim-R™.
  • The decrease in fourth quarter 2022 and increase in annual 2022 G&A expenses were both primarily driven by changes in non-cash stock-based compensation.
  • The increase in annual 2022 non-GAAP G&A expenses was driven by increased legal and corporate expenses and public company operating costs.

Lyell Immunopharma Presents New Data at SITC Highlighting its Growing Pipeline of T – Cell Reprogramming Technologies and Product Candidates Targeting Solid Tumors

Retrieved on: 
Monday, November 7, 2022
TIL, Company, Private Securities Litigation Reform Act, Research, Genetic, Maintenance, SAN, Stim, EPI, Abstract cell complex, GLOBE, CAR, Cell, Safety, Lyell, Toxic shock syndrome, COVID-19, Nasdaq, Immunotherapy, NR4A3, TCR, Phenotype, Securities and Exchange Commission (Philippines), Forward-looking statement, Technology, Goal, Security (finance), Melanoma, Society, SITC, Patient, ROR1, Vaccine, Pharmaceutical industry, Medical imaging

This includes new preclinical research on the potential to generate more potent T cells to provide durable anti-tumor functions against certain aggressive solid tumor cancers.

Key Points: 
  • This includes new preclinical research on the potential to generate more potent T cells to provide durable anti-tumor functions against certain aggressive solid tumor cancers.
  • Stackable Genetic and Epigenetic Reprogramming Technologies in LYL119, a Second-Generation CAR T-cell therapy targeting ROR1+ solid tumors
    Two presentations describe preclinical data on Lyells new, stackable reprogramming technologies NR4A3 knockout and Stim-R being incorporated in LYL119, a second-generation ROR1 targeting CAR T-cell product candidate.
  • Lyell plans to incorporate these two stackable genetic reprogramming technologies in its new product candidate, LYL119, currently in preclinical development.
  • Lyell is a clinical-stage T-cell reprogramming company dedicated to developing curative cell therapies for patients with solid tumors.

Lyell Immunopharma to Present Preclinical Data Highlighting New T-Cell Reprogramming Technologies and its Growing Pipeline at 2022 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Retrieved on: 
Wednesday, October 5, 2022
TCR, TIL, U.S. Securities and Exchange Commission, GSK, ROR1, SITC, Patient, Phenotype, Security (finance), Immunotherapy, Nasdaq, CAR, Technology, Private Securities Litigation Reform Act, Lyell, NY-ESO-1, Form 10-K, Goal, Company, Society, 2021 Essex County Council election, Toxic shock syndrome, GLOBE, Maintenance, Forward-looking statement, NR4A3, TILS, COVID-19, Vaccine, Medical imaging

The new preclinical data includes an abstract describing the effects of c-Jun overexpression in combination with NR4A3 gene knockout to enhance the functional activity of ROR1 CAR T cells.

Key Points: 
  • The new preclinical data includes an abstract describing the effects of c-Jun overexpression in combination with NR4A3 gene knockout to enhance the functional activity of ROR1 CAR T cells.
  • The combination of these two genetic reprogramming technologies is being incorporated in Lyells new product candidate, LYL119, a second generation investigational ROR1 targeting CAR T-cell therapy.
  • Our presence at SITC includes presentations of new preclinical data from both existing and new reprogramming technologies being deployed in our growing pipeline of therapeutic candidates for solid tumors, stated Dr. Gary Lee, chief scientific officer at Lyell.
  • Two presentations will feature preclinical data from LYL845, Lyells autologous TIL product candidate enhanced with Epi-R reprogramming technology, designed to create products with higher proportions of stem-like T cells.